ArticleBritish journal of cancer2009
Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 86 citations in OpenAlex.
- The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial.Nutrition journal · 2015Trial
- Article
- Beyond MIDAS: AnACS omega · 2026Article
- The circadian-melatonin axis in breast cancer metastasis: molecular mechanisms, organ-specific metastatic niches, and therapeutic opportunities.Frontiers in endocrinology · 2026Review
- Unveiling mysteries of aging: the potential of melatonin in preventing neurodegenerative diseases in older adults.Biogerontology · 2025Review
- Exploring the Efficacy of Melatonin in Alleviating Menopausal Symptoms in Breast Cancer Survivors: A Randomized, Double-Blind, Placebo-Controlled Study.Advanced biomedical research · 2025Article
- Circadian rhythms and breast cancer: from molecular level to therapeutic advancements.Journal of cancer research and clinical oncology · 2024Review
- Shining a spotlight on sleep disturbance-related cognitive impairment and relevance to menopause.Sleep · 2024Article
- Melatonin alleviates oxidative stress damage in mouse testes induced by bisphenol A.Frontiers in cell and developmental biology · 2024Article
- Review
- Like Brothers in Arms: How Hormonal Stimuli and Changes in the Metabolism Signaling Cooperate, Leading HPV Infection to Drive the Onset of Cervical Cancer.International journal of molecular sciences · 2022Review
- Melatonin for premenstrual syndrome: A potential remedy but not ready.Frontiers in endocrinology · 2022Review
- Review
- Sleep and endocrine therapy in breast cancer.Current opinion in endocrine and metabolic research · 2021Article
- A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer.Cancers · 2021Review
- Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer.International journal of molecular sciences · 2021Review
- The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions-Evidence for Estrogen as an Immunomodulator.Frontiers in cellular and infection microbiology · 2021Review
- From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review.Frontiers in veterinary science · 2021Review
- Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly?Turkish journal of medical sciences · 2020Review
- Melatonin: an endogenous miraculous indolamine, fights against cancer progression.Journal of cancer research and clinical oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelatonin reduces the development of breast cancer interfering with oestrogen-signalling pathways, and also inhibits aromatase activity and expression. Our objective was to study the promoters through which melatonin modifies aromatase expression, evaluate the ability of melatonin to regulate cyclooxygenases and assess whether the effects of melatonin are related to its effects on intracellular cAMP, in MCF-7 cells.
methodsTotal aromatase mRNA, aromatase mRNA promoter regions and cyclooxygenases mRNA expression were determined by real-time RT-PCR. PGE(2) and cAMP were measured by kits.
resultsMelatonin downregulated the gene expression of the two major specific aromatase promoter regions, pII and pI.3, and also that of the aromatase promoter region pI.4. Melatonin 1 nM was able to counteract the stimulatory effect of tetradecanoyl phorbol acetate on PGE(2) production and inhibit COX-2 and COX-1 mRNA expression. Melatonin 1 nM elicited a parallel time-dependent decrease in both cyclic AMP formation and aromatase mRNA expression.
conclusionsThis study shows that melatonin inhibits aromatase activity and expression by regulating the gene expression of specific aromatase promoter regions. A possible mechanism for these effects would be the regulation by melatonin of intracellular cAMP levels, mediated by an inhibition of cyclooxygenase activity and expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.